The Aliskiren Market size is expected to grow at an annual average of 4% during 2022-2028. Aliskiren (trade names Tekturna and Rasilez) is the first drug in a class called direct renin inhibitors. Used for essential (primary) hypertension. Direct renin inhibitors block the renin enzyme from triggering a process that helps control blood pressure. As a […]
